Key Sickle Cell Disease Drugs Market Players:
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
The global market of sickle cell disease drugs experiences a highly competitive nature. The leading key players like Pfizer, Novartis, and many more incorporated different competitive strategies to escalate market share in the global market. Innovative therapy presented in the market by Pfizer and Novartis resulted in to acquisition strong position in the competitive market. Affordable generics are considered the most effective strategy in emerging markets like India and Malaysia.
Companies like Sun Pharma and Cipla introduced the sickle cell disease drugs that are generic in nature and affordable in range. Companies like Bluebird Bio, Vertex, and many more invested in gene therapy, which upscaled the revenue accumulation rate for the business. Sanofi and Novartis developed a dominating market share in Europe with the help of biologics and patent protection programs.
Here are some leading players in the sickle cell disease drugs market:
|
Company Name |
Industry Focus |
Market Share (2024) |
|
Leading developer of SCD therapies, including Oxbryta |
18.2% |
|
|
Novartis AG (Switzerland) |
Produces Adakveo and focuses on precision medicine for SCD. |
15.4% |
|
Global Blood Therapeutics (U.S.) |
Specializes in Oxbryta |
12.3% |
|
Bluebird Bio (U.S.) |
Pioneering gene therapies for SCD |
10.4% |
|
Vertex Pharmaceuticals (U.S.) |
Developing CRISPR-based therapy |
9.4% |
|
Sanofi (France) |
Markets: Crizanlizumab in Europe & emerging markets. |
xx% |
|
Emmaus Life Sciences (U.S.) |
Produces Endari |
xx% |
|
Bristol-Myers Squibb (U.S.) |
Focuses on hematology drugs. |
xx% |
|
CSL Behring (Australia) |
Developing plasma-based therapies for SCD complications. |
xx% |
|
Daiichi Sankyo (Japan) |
Investing in small-molecule SCD drugs. |
xx% |
|
Takeda Pharmaceutical (Japan) |
Expanding rare disease portfolio, including SCD. |
xx% |
|
AstraZeneca (UK) |
Exploring anti-inflammatory SCD drugs. |
xx% |
|
GlaxoSmithKline (UK) |
Developing next-gen therapies, including gene editing. |
xx% |
|
Jazz Pharmaceuticals (Ireland) |
SCD-focused biotechs |
xx% |
|
Alnylam Pharmaceuticals (U.S.) |
Working on RNAi-based SCD therapies. |
xx% |
|
Dr. Reddy’s Laboratories (India) |
Leading generic hydroxyurea supplier |
xx% |
|
Cipla Ltd. (India) |
affordable SCD drugs |
xx% |
|
Bioverativ (U.S.) |
Focuses on SCD biologics |
xx% |
|
Hanmi Pharmaceutical (South Korea) |
Developing novel SCD small molecules |
xx% |
|
Pharmaniaga Berhad (Malaysia) |
Government-backed local SCD drug production. |
xx% |
Below are the areas covered for each company in the sickle cell disease drugs market:
